NASDAQ$CYRX

CryoPort Inc. · Q4 2022 earnings

Q4 2022 earnings · · Investor relations

Briefing

Cryoport's Q4 2022 earnings were reported, showing a revenue increase driven by demand for its supply chain solutions.

Cryoport reported a 7% increase in revenue for Q4 2022, reaching $60.4 million. The company's gross margin improved to 43.5%. Cryoport supported a total of 654 global clinical trials, with 79 in phase 3.

  • Total revenue for the fourth quarter of 2022 was $60.4 million, a 7% year-over-year increase.
  • Gross margin was 43.5% for the fourth quarter of 2022, compared to 41.0% in the fourth quarter of 2021.
  • Net loss for the three months ended December 31, 2022 was $9.4 million, compared to a net loss of $260.1 million for the same period in 2021.
  • Adjusted EBITDA was $0.7 million for the fourth quarter of 2022, compared to $2.1 million for the fourth quarter of 2021.

Headline financials

Total Revenue

$60.4M

Previous: $56.4M+6.9%
EPS (adj)

-$0.24

Previous: -$0.22-9.1%
Adjusted EBITDA

$700K

No prior period
Capital Expenditures

$7.86M

Previous: $8.33M-5.6%
Free Cash Flow

-$4.2M

Previous: -$5.71M+26.4%
Net Income

-$9.4M

Previous: -$7.1M-32.4%
Operating Income

-$11M

Previous: -$9.4M-17.4%
Gross Profit

$26.3M

Previous: $23.1M+13.7%
Cash & Equivalents

$523M

Previous: $629M-16.8%
Total Assets

$1.04B

Previous: $1.11B-6.7%
Stock-Based Comp

$5.33M

Previous: $4.18M+27.5%

Revenue & EPS history

CryoPort · Revenue · Quarterly

$60.4M

Q4 2022+6.9%vs Q4 2021
Beat estimate in 6 of 15 quarters(40%)
ActualEstimate

Forward guidance

The Company is providing revenue guidance for full year 2023 of $270 - $290 million, representing strong topline growth of 18% at the mid-point over 2022 revenue.

Tailwinds

  • Anticipated growth from ongoing support of global clinical trials.
  • A growing number of commercial cell and gene therapy products from our clients.
  • The expansion of cell and gene manufacturing capacity to meet patient demand.
  • Launch of new products and services, designed to further expand and strengthen our market position and create new diversifying revenue streams.
  • Strategic investments to support our continued growth.

Headwinds

  • Current macroeconomic challenges.
  • Ongoing effects of COVID-19 and related shut downs globally.
  • Supply chain constraints.
  • Inflationary pressures.
  • Economic uncertainty and the effects of foreign currency fluctuations.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2022

Historical avgQ4 2022

+2.2%

Avg return

Earnings day

+2.5%

Avg return

5 days after

+8.5%

Avg return

30 days after

49%

28 / 57 earnings

Positive

+31.6%

Q4 2013

Best reaction

-33.8%

Q3 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+19.4%+33.2%+58.2%
Q4 2025+2.9%-4.7%+3.3%
Q3 2025-8.2%-7.4%+3.5%
Q1 2025+23.4%+23.3%+23.7%
Q4 2024+30.6%-7.1%+5.7%
Q3 2024-3.6%-0.9%-8.6%
Q2 2024+3.9%+10.0%+9.8%
Q1 2024-17.5%-16.7%-30.6%
Q4 2023-12.3%-7.3%+10.3%
Q3 2023+8.9%+8.4%+46.7%
Q2 2023-0.2%+1.2%-5.0%
Q1 2023+13.9%+4.5%-6.3%
Q4 2022+13.7%+9.9%+15.3%
Q3 2022-33.8%-35.7%-26.5%
Q2 2022+6.8%+5.2%-16.1%
Q1 2022-8.5%-14.6%-2.8%
Q4 2021+9.3%+7.0%+1.9%
Q3 2021-1.0%-1.2%-22.8%
Q2 2021-1.5%-3.6%+2.9%
Q1 2021+9.0%+11.6%-2.4%
Q4 2020-0.7%-11.7%-12.5%
Q3 2020+5.0%+24.2%+12.8%
Q2 2020-2.0%-5.0%+55.5%
Q1 2020+2.0%+17.0%+22.6%
Q4 2019+2.1%+0.8%-11.9%
Q3 2019+1.4%+3.9%+5.6%
Q2 2019+19.7%+24.5%+2.3%
Q1 2019+12.5%+12.5%+17.7%
Q4 2018-0.6%+6.6%+22.3%
Q3 2018-1.0%-9.4%-2.0%
Q2 2018-1.6%-14.7%-6.5%
Q1 2018+11.8%+23.0%+67.4%
Q4 2017+3.8%+6.4%-7.0%
Q3 2017-15.1%-22.9%-10.5%
Q2 2017-2.0%+3.6%+28.6%
Q1 2017+8.2%+9.0%+46.9%
Q4 2016+23.7%+9.0%+23.7%
Q2 2016-7.5%
Q1 2016+10.2%
Q4 2015-3.0%
Q3 2015+7.5%
Q2 2015-14.4%
Q1 2015-2.2%
Q4 2014+6.4%
Q3 2014-5.6%
Q4 2013+31.6%
Q3 2013-8.0%
Q2 2013+5.3%
Q1 2013+0.0%
Q4 2012-3.1%
Q3 2012-10.8%
Q2 2012-8.0%
Q1 2012-2.7%
Q1 2010+11.2%
Q3 2009+1.4%
Q2 2009-2.8%
Q1 2009+0.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro